// App-Quantinova.ai

5004 : APX005M, a humanized anti-CD40 antibody with strong immune-modulatory activities capable of tumor eradication in vivo

Researchers

Presenter

  • Pia Bjorck

Principal Investigators

  • Erin Filbert

  • Xiaodong Yang

  • Ovidiu C. Trifan

Medical Centers

  • Apexigen, San Carlos, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Lymphomas

Biomarkers

  • Soluble CD40-ligand

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved